Skip to main content
Top
Published in: Hepatology International 4/2014

01-10-2014 | Original Article

Diastolic cardiac dysfunction is a predictor of dismal prognosis in patients with liver cirrhosis

Authors: Dimitrios S. Karagiannakis, Jiannis Vlachogiannakos, Georgios Anastasiadis, Irini Vafiadis-Zouboulis, Spiros D. Ladas

Published in: Hepatology International | Issue 4/2014

Login to get access

Abstract

Background and purpose

Left ventricular diastolic dysfunction (LVDD) constitutes the prominent characteristic of cirrhotic cardiomyopathy, but its relevance on the clinical course of cirrhotic patients has not been clearly defined. The aim of the study was to evaluate the relationship of LVDD with the severity and etiology of liver disease and to investigate whether it affects the outcome of cirrhotic patients.

Methods

Cardiac function of 45 cirrhotics was studied by a tissue Doppler imaging echocardiography. Diagnosis of LVDD was made according to the latest guidelines of the American Society of Echocardiography. All patients were followed up for a period of 2 years. Death or liver transplantation was the endpoint of the study.

Results

LVDD was found in 17 (38 %) of 45 patients. Its presence was not found to be associated with the etiology and stage of cirrhosis, but its severity was directly correlated with the Child-Pugh score. At the end of follow-up, 14 patients had died; 9 had LVDD (9/17, 53 %) and 5 had not (5/28, 18 %). Patients who died at the beginning of observation period had a higher Child-Pugh and MELD score, higher BNP, lower albumin and more prolonged QTc. On Kaplan-Meier analysis, patients with LVDD had statistically significantly worse prognosis compared to those without (p = 0.013, log rank: 5.495). Low albumin values (p = 0.003) and presence of LVDD (p = 0.017) were independent predictive factors of mortality.

Conclusions

LVDD is a common complication of cirrhosis. As its development seems to be related to a worse prognosis, patients with LVDD must be under a strict follow-up.
Literature
1.
go back to reference Schrier RW, Arroyo V, Bernardi M, Epstein M, Henriksen JH, Rode’s J. Peripheral artery vasodilatation hypothesis: a proposal for the initiation of renal sodium and water retention in cirrhosis. Hepatology 1988;5:1151–1157CrossRef Schrier RW, Arroyo V, Bernardi M, Epstein M, Henriksen JH, Rode’s J. Peripheral artery vasodilatation hypothesis: a proposal for the initiation of renal sodium and water retention in cirrhosis. Hepatology 1988;5:1151–1157CrossRef
2.
go back to reference Iwakiri Y, Groszmann RJ. The hyperdynamic circulation of chronic liver diseases: from the patient to the molecule. Hepatology 2006;43:S121–S131PubMedCrossRef Iwakiri Y, Groszmann RJ. The hyperdynamic circulation of chronic liver diseases: from the patient to the molecule. Hepatology 2006;43:S121–S131PubMedCrossRef
3.
go back to reference Salermo F, Cazzaniga M, Gobbo G. Pharmacological treatment of hepatorenal syndrome: a note of optimism. J Hepatol 2007;47:729–731CrossRef Salermo F, Cazzaniga M, Gobbo G. Pharmacological treatment of hepatorenal syndrome: a note of optimism. J Hepatol 2007;47:729–731CrossRef
4.
go back to reference Moller S, Henriksen JH. The systemic circulation in cirrhosis. In Gines P, Arroyo V, Rodes J, Schrier RW, editors. Ascites and Renal Dysfunction in Liver Disease. 2nd ed. Malden: Blackwell; 2005. 139–155 Moller S, Henriksen JH. The systemic circulation in cirrhosis. In Gines P, Arroyo V, Rodes J, Schrier RW, editors. Ascites and Renal Dysfunction in Liver Disease. 2nd ed. Malden: Blackwell; 2005. 139–155
5.
go back to reference Krag A, Bendtsen F, Burroughs AK, Moller S. The cardiorenal link in advanced cirrhosis. Med Hypotheses 2012;79:53–55PubMedCrossRef Krag A, Bendtsen F, Burroughs AK, Moller S. The cardiorenal link in advanced cirrhosis. Med Hypotheses 2012;79:53–55PubMedCrossRef
6.
go back to reference Timoh T, Protano MA, Wagman G, Bloom M, Vittorio TJ. A perspective on cirrhotic cardiomyopathy. Transplant Proc 2011;43:1649–1653PubMedCrossRef Timoh T, Protano MA, Wagman G, Bloom M, Vittorio TJ. A perspective on cirrhotic cardiomyopathy. Transplant Proc 2011;43:1649–1653PubMedCrossRef
7.
go back to reference Moller S, Hove JD, Dixen U, Bendtsen F. New insights into cirrhotic cardiomyopathy. Int J Cardiol 2013;167:1101–1108PubMedCrossRef Moller S, Hove JD, Dixen U, Bendtsen F. New insights into cirrhotic cardiomyopathy. Int J Cardiol 2013;167:1101–1108PubMedCrossRef
8.
go back to reference Bernardi M, Maggioli C, Dibra V, Zaccherini G. QT interval prolongation in liver cirrhosis: innocent bystander or serious threat? Expert Rev Gastroenterol Hepatol 2012;6:57–66PubMedCrossRef Bernardi M, Maggioli C, Dibra V, Zaccherini G. QT interval prolongation in liver cirrhosis: innocent bystander or serious threat? Expert Rev Gastroenterol Hepatol 2012;6:57–66PubMedCrossRef
9.
go back to reference Wiese S, Hove JD, Bendtsen F, Moller S. Cirrhotic cardiomyopathy: pathogenesis and clinical relevance. Nat Rev Gastroenterol Hepatol 2013;11:177–186PubMedCrossRef Wiese S, Hove JD, Bendtsen F, Moller S. Cirrhotic cardiomyopathy: pathogenesis and clinical relevance. Nat Rev Gastroenterol Hepatol 2013;11:177–186PubMedCrossRef
10.
go back to reference Pozzi M, Redaelli E, Ratti L, Poli G, Guidi C, Milanese M, et al. Time-course of diastolic dysfunction in different stages of chronic HCV related liver diseases. Minerva Gastroenterol Dietol 2005;51:179–186PubMed Pozzi M, Redaelli E, Ratti L, Poli G, Guidi C, Milanese M, et al. Time-course of diastolic dysfunction in different stages of chronic HCV related liver diseases. Minerva Gastroenterol Dietol 2005;51:179–186PubMed
11.
go back to reference Guilo P, Mansourati J, Maheu B, Etienne Y, Provost K, Simon O, et al. Long-term prognosis in patients with alcoholic cardiomyopathy and severe heart failure after total abstinence. Am J Cardiol 1997;79(9):1276–1278CrossRef Guilo P, Mansourati J, Maheu B, Etienne Y, Provost K, Simon O, et al. Long-term prognosis in patients with alcoholic cardiomyopathy and severe heart failure after total abstinence. Am J Cardiol 1997;79(9):1276–1278CrossRef
12.
go back to reference Nagueh SF, Appleton CP, Gillebert TC, Marino PN, Oh JK, Smiseth OA, et al. Recommendations for the evaluation of left ventricular diastolic function by echocardiography. J Am Soc Echocardiogr 2009;22:107–133PubMedCrossRef Nagueh SF, Appleton CP, Gillebert TC, Marino PN, Oh JK, Smiseth OA, et al. Recommendations for the evaluation of left ventricular diastolic function by echocardiography. J Am Soc Echocardiogr 2009;22:107–133PubMedCrossRef
13.
go back to reference Klein AL, Burstow DJ, Talik AJ, Zachariak PK, Bailey KR, Seward JB. Effects of age on left ventricular dimensions and filling dynamics in 117 normal persons. Mayo Clin Proc 1994;69:212–224PubMedCrossRef Klein AL, Burstow DJ, Talik AJ, Zachariak PK, Bailey KR, Seward JB. Effects of age on left ventricular dimensions and filling dynamics in 117 normal persons. Mayo Clin Proc 1994;69:212–224PubMedCrossRef
14.
go back to reference Kazankov K, Holland-Fischer P, Andersen NH, Torp P, Sloth E, Aagaard NK, et al. Resting myocardial dysfunction in cirrhosis quantified by tissue Doppler imaging. Liver Int 2011;31:534–540PubMedCrossRef Kazankov K, Holland-Fischer P, Andersen NH, Torp P, Sloth E, Aagaard NK, et al. Resting myocardial dysfunction in cirrhosis quantified by tissue Doppler imaging. Liver Int 2011;31:534–540PubMedCrossRef
15.
go back to reference Sampaio F, Pimenta J, Bettencourt N, Fontes‐Carvalho R, Silva AP, Valente J, et al. Systolic and diastolic dysfunction in cirrhosis: a tissue-Doppler and speckle tracking echocardiography study. Liver int 2013;33:1158–1165PubMedCrossRef Sampaio F, Pimenta J, Bettencourt N, Fontes‐Carvalho R, Silva AP, Valente J, et al. Systolic and diastolic dysfunction in cirrhosis: a tissue-Doppler and speckle tracking echocardiography study. Liver int 2013;33:1158–1165PubMedCrossRef
16.
go back to reference Lee RF, Glenn TK, Lee SS. Cardiac dysfunction in cirrhosis. Best Pract Res Clin Gastroenterol 2007;21:125–140PubMedCrossRef Lee RF, Glenn TK, Lee SS. Cardiac dysfunction in cirrhosis. Best Pract Res Clin Gastroenterol 2007;21:125–140PubMedCrossRef
17.
18.
19.
go back to reference Cazzaniga M, Salerno F, Pagnozzi G, Dionigi E, Visentin S, Cirello I, et al. Diastolic dysfunction is associated with poor survival in cirrhotic patients with transjugular intrahepatic portosystemic shunt. Gut 2007;56:869–875PubMedCrossRefPubMedCentral Cazzaniga M, Salerno F, Pagnozzi G, Dionigi E, Visentin S, Cirello I, et al. Diastolic dysfunction is associated with poor survival in cirrhotic patients with transjugular intrahepatic portosystemic shunt. Gut 2007;56:869–875PubMedCrossRefPubMedCentral
20.
go back to reference Rabie RN, Cazzaniga M, Salerno F, Wong F. The use of E/A ratio as a predictor of outcome in cirrhotic patients treated with transjugular intrahepatic portosystemic shunt. Am J Gastroenterol 2009;104:2458–2466PubMedCrossRef Rabie RN, Cazzaniga M, Salerno F, Wong F. The use of E/A ratio as a predictor of outcome in cirrhotic patients treated with transjugular intrahepatic portosystemic shunt. Am J Gastroenterol 2009;104:2458–2466PubMedCrossRef
21.
go back to reference Ripoll C, Catalina MV, Yotti R, Olmedilla L, Pérez-Peña J, Iacono O, et al. Cardiac dysfunction during liver transplantation: incidence and preoperative predictors. Transplantation 2008;85:1766–1772PubMedCrossRef Ripoll C, Catalina MV, Yotti R, Olmedilla L, Pérez-Peña J, Iacono O, et al. Cardiac dysfunction during liver transplantation: incidence and preoperative predictors. Transplantation 2008;85:1766–1772PubMedCrossRef
22.
go back to reference Holt EW, Woo G, Trilesskaya M, Haeusslein EA, Shaw RE, Frederick RT. Diastolic dysfunction defined by E/A ratio < 1 on 2-D echo is an independent predictor of liver transplantation or death in patient with cirrhosis. J Hepatol 2011;54:S245–S246CrossRef Holt EW, Woo G, Trilesskaya M, Haeusslein EA, Shaw RE, Frederick RT. Diastolic dysfunction defined by E/A ratio < 1 on 2-D echo is an independent predictor of liver transplantation or death in patient with cirrhosis. J Hepatol 2011;54:S245–S246CrossRef
23.
go back to reference Ruiz-del-Arbol L, Achecar L, Serradilla R, Rodríguez‐Gandía MÁ, Rivero M, Garrido E, et al. Diastolic dysfunction is a predictor of poor outcomes in patients with cirrhosis, portal hypertension and I normal creatinine. Hepatology 2013;58:1732–1741PubMedCrossRef Ruiz-del-Arbol L, Achecar L, Serradilla R, Rodríguez‐Gandía MÁ, Rivero M, Garrido E, et al. Diastolic dysfunction is a predictor of poor outcomes in patients with cirrhosis, portal hypertension and I normal creatinine. Hepatology 2013;58:1732–1741PubMedCrossRef
24.
go back to reference Nazar A, Guevara M, Sitges M, Terra C, Solà E, Guigou C, et al. Left ventricular function assessed by echocardiography in cirrhosis: Relationship to systemic hemodynamics and renal dysfunction. J Hepatol 2013;58:51–57PubMedCrossRef Nazar A, Guevara M, Sitges M, Terra C, Solà E, Guigou C, et al. Left ventricular function assessed by echocardiography in cirrhosis: Relationship to systemic hemodynamics and renal dysfunction. J Hepatol 2013;58:51–57PubMedCrossRef
25.
go back to reference Merli M, Calicchia A, Ruffa A, Pellicori P, Riggio O, Giusto M, et al. Cardiac dysfunction in cirrhosis is not associated with the severity of liver disease. Euro J Int Med 2013;24:172–176CrossRef Merli M, Calicchia A, Ruffa A, Pellicori P, Riggio O, Giusto M, et al. Cardiac dysfunction in cirrhosis is not associated with the severity of liver disease. Euro J Int Med 2013;24:172–176CrossRef
26.
go back to reference Alexopoulou A, Papatheodoridis G, Pouriki S, Chrysohoou C, Raftopoulos L, Stefanadis C, et al. Diastolic myocardial dysfunction does not affect survival in patients with cirrhosis. Transpl Int 2012;25:1174–1181PubMedCrossRef Alexopoulou A, Papatheodoridis G, Pouriki S, Chrysohoou C, Raftopoulos L, Stefanadis C, et al. Diastolic myocardial dysfunction does not affect survival in patients with cirrhosis. Transpl Int 2012;25:1174–1181PubMedCrossRef
27.
go back to reference Henriksen JH, Goetze JP, Fuglsang S, Christensen E, Bendtsen F, Moller S. Increased circulating pro-brain natriuretic peptide (proBNP) and brain natriuretic peptide (BNP) in patients with cirrhosis: relation to cardiovascular dysfunction and severity of disease. Gut 2003;52:1511–1157PubMedCrossRefPubMedCentral Henriksen JH, Goetze JP, Fuglsang S, Christensen E, Bendtsen F, Moller S. Increased circulating pro-brain natriuretic peptide (proBNP) and brain natriuretic peptide (BNP) in patients with cirrhosis: relation to cardiovascular dysfunction and severity of disease. Gut 2003;52:1511–1157PubMedCrossRefPubMedCentral
28.
go back to reference Pimenta J, Paulo C, Gomes A, Silva S, Rocha-Goncalves F, Bettencourt P. B-type natriuretic peptide is related to cardiac function and prognosis in hospitalized patients with decompensated cirrhosis. Liver Int 2010;30:1059–1066PubMedCrossRef Pimenta J, Paulo C, Gomes A, Silva S, Rocha-Goncalves F, Bettencourt P. B-type natriuretic peptide is related to cardiac function and prognosis in hospitalized patients with decompensated cirrhosis. Liver Int 2010;30:1059–1066PubMedCrossRef
29.
go back to reference Bal JS, Thuluvath PJ. Prolongation of QTc inteval: relationship with etiology and severity of liver disease, mortality and liver transplantation. Liver int 2003;23:243–248PubMedCrossRef Bal JS, Thuluvath PJ. Prolongation of QTc inteval: relationship with etiology and severity of liver disease, mortality and liver transplantation. Liver int 2003;23:243–248PubMedCrossRef
30.
go back to reference Trevisani F, Di Micoli A, Zambruni A, Biselli M, Santi V, Erroi V, et al. QT interval prolongation by acute gastrointestinal bleeding in patients with cirrhosis. Liver Int 2012;32:1510–1515PubMedCrossRef Trevisani F, Di Micoli A, Zambruni A, Biselli M, Santi V, Erroi V, et al. QT interval prolongation by acute gastrointestinal bleeding in patients with cirrhosis. Liver Int 2012;32:1510–1515PubMedCrossRef
Metadata
Title
Diastolic cardiac dysfunction is a predictor of dismal prognosis in patients with liver cirrhosis
Authors
Dimitrios S. Karagiannakis
Jiannis Vlachogiannakos
Georgios Anastasiadis
Irini Vafiadis-Zouboulis
Spiros D. Ladas
Publication date
01-10-2014
Publisher
Springer India
Published in
Hepatology International / Issue 4/2014
Print ISSN: 1936-0533
Electronic ISSN: 1936-0541
DOI
https://doi.org/10.1007/s12072-014-9544-6

Other articles of this Issue 4/2014

Hepatology International 4/2014 Go to the issue
Live Webinar | 27-06-2024 | 18:00 (CEST)

Keynote webinar | Spotlight on medication adherence

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

WHO estimates that half of all patients worldwide are non-adherent to their prescribed medication. The consequences of poor adherence can be catastrophic, on both the individual and population level.

Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.

Prof. Kevin Dolgin
Prof. Florian Limbourg
Prof. Anoop Chauhan
Developed by: Springer Medicine
Obesity Clinical Trial Summary

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine

Highlights from the ACC 2024 Congress

Year in Review: Pediatric cardiology

Watch Dr. Anne Marie Valente present the last year's highlights in pediatric and congenital heart disease in the official ACC.24 Year in Review session.

Year in Review: Pulmonary vascular disease

The last year's highlights in pulmonary vascular disease are presented by Dr. Jane Leopold in this official video from ACC.24.

Year in Review: Valvular heart disease

Watch Prof. William Zoghbi present the last year's highlights in valvular heart disease from the official ACC.24 Year in Review session.

Year in Review: Heart failure and cardiomyopathies

Watch this official video from ACC.24. Dr. Biykem Bozkurt discusses last year's major advances in heart failure and cardiomyopathies.